RxDoctor Payments Data

Adam Keesling, MD

Family Medicine · Arkansas City, KSNPI 1881956001

Payments from drug & device makers

$353in general payments, 2019–2025

Across 16 payments — averaging $22.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$118
  • Novo Nordisk$53
  • Amgen$46
  • E.r. Squibb & Sons, L.L.C.$35
  • Johnson & Johnson$25
  • Sanofi Pasteur Inc.$23
  • plus $52 from 4 others

What the payments were for

  • Food & beverage$28180%
  • Education$4914%
  • Gifts$237%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$353 in reported general payments places this provider in the 40th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$134,862
Medicare patients
266
Services billed
4,360

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide84$79,419
MounjaroTirzepatide39$49,042
ArexvyRsvpref3 Antigen/As01e/Pf128$39,468
EliquisApixaban31$30,557
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$26,986
XareltoRivaroxaban17$20,446
JanuviaSitagliptin Phosphate15$20,019
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$12,887
ShingrixVaricella-Zoster Ge/As01b/Pf54$11,724
Tresiba Flextouch U-200Insulin Degludec14$10,568
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$7,302
JardianceEmpagliflozin11$6,468
Novolog FlexpenInsulin Aspart16$6,385
Fluticasone-SalmeterolFluticasone Propion/Salmeterol36$5,400
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$4,376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$53$79,41984 claims
Johnson & JohnsonXarelto$25$20,44617 claims
Boehringer IngelheimJardiance$13$6,46811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Arkansas City

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →